Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00162799
Recruitment Status : Completed
First Posted : September 13, 2005
Last Update Posted : June 23, 2006
Information provided by:
J. Uriach and Company

Brief Summary:
To explore the efficacy of triflusal in the attenuation of insulin resistance in human obesity. Triflusal is a salicylate compound approved in several countries as antithrombotic agent (antiplatelet). The hypothesis is to explore if there is a reduction of obesity-induced insulin resistance by triflusal.

Condition or disease Intervention/treatment Phase
Insulin Resistance Drug: Triflusal (DCI) Phase 2

Detailed Description:

Double-blind, randomized, cross-over (three periods) with two dose levels of triflusal, placebo-controlled.

Interventions: treatment periods Triflusal 600 mg/d, 15 days Triflusal 900 mg/d , 15 days placebo, 15 days

Washout period: 30 days

Study Type : Interventional  (Clinical Trial)
Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Phase IIa Study of Triflusal in the Attenuation of Insulin Resistance in Men and Woman With Obesity
Study Start Date : July 2002
Study Completion Date : December 2004

Primary Outcome Measures :
  1. Increase of insulin sensitivity in apparently healthy men and woman evaluate by means of i.v. glucose tolerance test (PTEVGMR).

Secondary Outcome Measures :
  1. Reduction antropometric measures associated with insulin resistance and arterial hypertension.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   35 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Ages 35 to 60 years old

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00162799

Unitat de Diabetologia, Endocrinologia y Nutrición Hosp Josep Trueta
Girona, Spain, 17007
Sponsors and Collaborators
J. Uriach and Company
Principal Investigator: Jose Manuel Fernández del Real, Dr Unidad Diabetología. Serv Endocrino Hosp Josep Trueta Identifier: NCT00162799     History of Changes
Other Study ID Numbers: ICO5TRI/2/01
First Posted: September 13, 2005    Key Record Dates
Last Update Posted: June 23, 2006
Last Verified: September 2005

Keywords provided by J. Uriach and Company:
insulin resistance and inflamation
insulin sensitibity
obesity-induced insuline resistence
obesity-diabetes link
insulin resistance in obesity health adults

Additional relevant MeSH terms:
Insulin Resistance
Nutrition Disorders
Body Weight
Signs and Symptoms
Glucose Metabolism Disorders
Metabolic Diseases
Insulin, Globin Zinc
Hypoglycemic Agents
Physiological Effects of Drugs
Platelet Aggregation Inhibitors
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action